Scientists are exploring the potential of virus collections that target bacteria as a new weapon against infections that no longer respond to traditional antibiotics. An estimated 38 trillion bacteria live in the human body, and only a small share cause disease; when those pathogens develop resistance, treatment options shrink. Interest is growing in solutions that complement drugs rather than replace them, and one promising avenue is the systematic assembly of libraries of bacteriophages for clinical use.
Unlike broad‑spectrum antibiotics, bacteriophages are viruses that infect specific bacterial species. Collections or “libraries” of well‑characterized phages would allow clinicians and laboratories to match a patient’s infecting strain with an effective phage or phage cocktail, potentially delivering targeted antibacterial activity while preserving the wider microbiome. Curated repositories would include isolates with documented host ranges, genomic sequences and production protocols so therapies can be selected rapidly in acute settings.
Translating that idea into routine care faces practical hurdles. Phages must be rigorously characterized for safety and for absence of undesirable genes; manufacturing must meet pharmaceutical quality standards; and regulatory pathways remain uneven across jurisdictions. Clinical evaluation also requires standardized methods to measure efficacy and monitor for bacterial resistance to phages. Coordination at an international level, including norms and surveillance systems advocated by organizations such as WHO, will be important to ensure consistent quality and equitable access.
If these obstacles can be addressed, phage libraries could become a complementary option for infections that are difficult to treat with antibiotics alone. Their greatest immediate value may lie in hospital and other high‑risk settings, where rapid pairing of pathogen and phage could curb outbreaks. However, realizing that potential will require investment in infrastructure, clear regulatory frameworks and robust clinical evidence to define when and how phage therapies should be used alongside established antimicrobial stewardship efforts and surveillance of antibiotic resistance.
